Description

Sofosbuvir is a nucleotide analog prodrug that inhibits the HCV NS5B RNA-dependent RNA polymerase, essential for viral replication Nature+15PMC+15European Medicines Agency (EMA)+15. It is the active component in the brand Sovaldi, characterized by a yellow, film-coated tablet containing 400?mg of sofosbuvir.

This formulation is ideal for preclinical research focusing on viral replication, drug resistance mechanisms, combination therapy models, and biochemical pharmacology involving HCV. Although clinically approved for hepatitis C treatment, this product is supplied for laboratory research and wholesale use.

Sofosbuvir Tablets Product Specifications

Sofosbuvir Tablets Mechanism of Action

Sofosbuvir is metabolized in hepatocytes to its active triphosphate form, which competitively blocks the HCV NS5B polymerase, causing premature termination of RNA synthesis . This inhibition applies across all major HCV genotypes and has a high barrier to resistance.

Sofosbuvir Tablets Research Applications

• Viral replication assays targeting NS5B polymerase

• Resistance profiling for direct-acting antivirals (DAAs)

• Combination antiviral screening (e.g., sofosbuvir + velpatasvir)

• Studies of activation/metabolism pathways in hepatocytes

• Mechanistic research into HCV virology and pharmacodynamics

Safety & Handling

• Use standard laboratory PPE (lab coat, gloves, eye protection)

• Conduct all handling in research-grade conditions

• Store in a sealed container away from heat and moisture

• Not for human or veterinary clinical use

Core Keywords

sofosbuvir tablets 400mg, Sovaldi, CAS 1190307-88-0, HCV NS5B inhibitor, HCV research compound, nucleotide analog sofosbuvir, antiviral screening drug, Gilead sofosbuvir tablet, hepatitis C lab reagent

Research Use Disclaimer

This product is intended only for laboratory and preclinical research. It is not approved for clinical, diagnostic, therapeutic, or veterinary application. Misuse may result in health or regulatory consequences. Use responsibly following institutional protocols.